The Regulatory Chimera: How Cannabis Rescheduling Will Transform Pharmaceutical Research
The move from Schedule I to Schedule III promises to unleash cannabis research, but pharmaceutical companies face a deeper challenge: a plant that resists the very methods the industry uses to prove medicines work.